8 January 2025 - Complement Therapeutics today announced that the US FDA has granted fast track designation for CTx001, the company's lead gene therapy candidate for the treatment of geographic atrophy secondary to age-related macular degeneration.

CTx001 is a novel adenovirus associated gene therapy designed to deliver a truncated version of complement receptor 1, with the potential for long-term potent modulation of the classical and alternative pathways of the complement cascade.

Read Complement Therapeutics press release